top of page

Search Results

310 results found for "LASEREDD Therapeutics"

Programs (1)

View All

Posts (244)

View All

Other Pages (63)

  • Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer

    Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and

  • Ep 122 with Dr. Nicolas Gilles

    He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic

  • Ep 81 with Dr. Christel Menet

    I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.

View All

Events (2)

View All

Powered by


All Rights Reserved © 2020 - 2024

Dr. GPCR CORP is a 501(c)(3) non profit organization

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
bottom of page